Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyowa Kirin Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has signed voluntarily the written informed consent form to participate in this study.
Subject has been diagnosed as pustular psoriasis or psoriatic erythroderma.
Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.
You may not be if
Subject with psoriatic erythroderma has involved Body surface area (BSA) of lesion \< 80% at baseline.
Subject diagnosed with guttate psoriasis, medication-induced or medication-exacerbated psoriasis.
Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of KHK4827 on psoriasis.
Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection
Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.
Subject has used Ultra Violet B (UVB) therapy within 14 days of the first dose or Ultra Violet A (UVA) (with or without psoralen) within 28 days of the first dose.
Subject has used etanercept, adalimumab, infliximab or ustekinumab within 1 week, 2 weeks, 8 weeks or 12 weeks of the first dose, respectively.
Subject has stopped ustekinumab or other anti-Interleukin (IL)-23 biologics therapy due to lack of efficacy
Subject has used live vaccine within 3 months of the first dose
Subject has previously used an anti-IL-17 biologic therapy
Clareo Health | An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis
